Testing Smaller Treatment Margins in Radiotherapy for Prostate Cancer
Tests precise radiotherapy with reduced safety margins in adults with prostate cancer.
Plain-language title generated from the registry record
Registry title: Stereotactic Radiotherapy of Prostate Cancer With Reduction of Safety Margins
Key facts
- Where
- Ostrava, CzechiaSee the site
Where in Czechia
- University Hospital OstravaOstrava, CzechiaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University Hospital Ostrava
- Trial code
- NCT06665932
- Record updated
- 12 November 2024
- Original description
The study aims to reduce the PTV (Planning Target Volume) safety margins to 1-2 mm in stereotactic prostate radiotherapy for low- and medium-risk prostate cancers while maintaining a dose of 36.25 Gy in 5 fractions per day. By reducing the hems, the investigators expect a reduction of acute and late toxicity on the organs at risk, dominantly the urethra, bladder, penile bulb, and rectum, and an improvement in the quality of life.Read full original descriptionShow less
Stereotactic Radiotherapy of Prostate Cancer With Reduction of Safety Margins
The study aims to reduce the PTV (Planning Target Volume) safety margins to 1-2 mm in stereotactic prostate radiotherapy for low- and medium-risk prostate cancers while maintaining a dose of 36.25 Gy in 5 fractions per day. By reducing the hems, the investigators expect a reduction of acute and late toxicity on the organs at risk, dominantly the urethra, bladder, penile bulb, and rectum, and an improvement in the quality of life.
Inclusion: histologically verified, localized prostate cancer without regional lymphadenopathy or distant metastases; low or intermediate risk - favorable risk; staging according to NCCN recommendations:; low risk: no staging required; intermediate risk- favorable risk: CT abdomen and pelvis; PSA up to 15; age over 18 years; signed informed consent form; suitable position of fiducials (to be determined by the physicist).
Exclusion: previous treatment with radiotherapy to the pelvic area; a histological type other than acinar adenocarcinoma; the presence of local lymphadenopathy or distant metastases; a dominant lesion in the periphery that is in contact with the capsule or grows through it; PSA over 15; unsatisfactory position of fiducials (to be determined by the physicist).